Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain

Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet